Browse News
Filter News
Found 72 articles
-
Allogene Therapeutics' French partner Servier has withdrawn all involvement in the development of Allogene’s anti-CD19 products, allowing Allogene to license its CD19 products outside the U.S.
-
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
5/6/2021
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic chimeric antigen receptor (CAR) T-cells in the field of immuno-oncology, today announced its results for the three-month period ending March 31, 2021.
-
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
3/4/2021
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers
-
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
11/5/2020
Sponsored program at ASH 2020–Oral presentation of initial data for BALLI-01 clinical trial evaluating UCART22 product candidate in adult patients with R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
-
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020
8/5/2020
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the three-month and six-month periods ended June 30, 2020.
-
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020
5/6/2020
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), today announced its results for the three-month period ended March 31, 2020.
-
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
3/4/2020
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced its results for the fourth quarter 2019 and full year ended December 31, 2019.
-
Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products
3/4/2020
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), and Servier, an international pharmaceutical company, today announced the execution of the amendment to the agreement initially signed between the two companies in 2014 and modified in 2019.
-
Cellectis and Servier Expand Collaboration on UCART19 Products
2/18/2020
Cellectis grants additional rights to Servier to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19, including ALLO-501A
-
Servier Showcases Robust Presence at ASH 2019
12/4/2019
A complete listing of this year's Servier abstracts* are available on the ASH website.
-
Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting
11/6/2019
Data Reinforce Scientific Foundation of ALLO-715 (anti-BCMA) in Multiple Myeloma and ALLO-819 (anti-FLT3) in Acute Myeloid Leukemia
-
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
11/6/2019
First patient dosed with UCARTCS1 in MELANI-01 Phase 1 dose-escalation clinical trial for Relapsed/Refractory Multiple Myeloma
-
Allogene Therapeutics Reports Third Quarter 2019 Financial Results
11/5/2019
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, provided a corporate update and reported financial results for the quarter ended September 30, 2019.
-
Cellectis Reports Financial Results for Second Quarter and First Six Months 2019
8/6/2019
FDA approved IND for UCARTCS1 – first allogeneic CAR T-cell product candidate in multiple myeloma
-
How can you selectively target and destroy cancerous T-cells using other T-cells? This question has plagued researches hoping to apply chimeric antigen receptor (CAR) T-cell therapies to T-cell cancers.
-
CAR-T Therapy Development on the Rise
6/11/2019
CAR-T cells are T-cells that have been engineered to express a receptor (called a chimeric antigen receptor, or CAR) that recognizes a specific type of cancer cell. -
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
-
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
4/2/2019
Successful manufacturing and release of GMP vials of UCARTCS1
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
Cellectis Reports 4th Quarter and Full Year 2018 Financial Results
3/11/2019
Cellectis S.A. announced its results for the fourth quarter 2018 and full year ended December 31, 2018.